- Home
- ACAD
as 05-20-2024 10:33am EST
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
| Founded: | 1993 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 2.4B | IPO Year: | 2004 |
| Target Price: | $29.37 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Buy | Number of Analysts: | 19 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.65 - $33.99 | Next Earning Date: | 05-08-2024 |
| Revenue: | $813,806,000 | Revenue Growth: | 56.43% |
| Revenue Growth (this year): | 35.79% | Revenue Growth (next year): | 13.14% |
Share on Social Networks:
Stock Insider Trading Activity of ACADIA Pharmaceuticals Inc. (ACAD)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Schneyer Mark C. | ACAD | EVP, CHIEF FINANCIAL OFFICER | May 1 '24 | Sell | $16.94 | 3,503 | $59,340.82 | 32,053 | SEC Form 4 |
| Teehan Brendan | ACAD | EVP, COO, HEAD OF COMMERCIAL | May 1 '24 | Sell | $16.94 | 3,477 | $58,900.38 | 42,133 | SEC Form 4 |
| Kihara James | ACAD | PRINCIPAL ACCOUNTING OFFICER | May 1 '24 | Sell | $16.94 | 1,326 | $22,462.44 | 14,370 | SEC Form 4 |
| DAVIS STEPHEN | ACAD | CEO | May 1 '24 | Sell | $16.94 | 11,427 | $193,573.38 | 155,231 | SEC Form 4 |
| Teehan Brendan | ACAD | EVP, COO, HEAD OF COMMERCIAL | Apr 5 '24 | Sell | $17.87 | 2,568 | $45,890.16 | 38,796 | SEC Form 4 |
| DAVIS STEPHEN | ACAD | CEO | Apr 5 '24 | Sell | $17.87 | 8,858 | $158,292.46 | 161,983 | SEC Form 4 |
| DAVIS STEPHEN | ACAD | CEO | Apr 5 '24 | Sell | $17.87 | 17,716 | $316,584.92 | 144,267 | SEC Form 4 |
| Kihara James | ACAD | PRINCIPAL ACCOUNTING OFFICER | Apr 5 '24 | Sell | $17.87 | 1,028 | $18,370.36 | 13,862 | SEC Form 4 |
| Kihara James | ACAD | PRINCIPAL ACCOUNTING OFFICER | Apr 5 '24 | Sell | $17.87 | 762 | $13,616.94 | 13,100 | SEC Form 4 |
| Schneyer Mark C. | ACAD | EVP, CHIEF FINANCIAL OFFICER | Apr 5 '24 | Sell | $17.87 | 2,716 | $48,534.92 | 28,742 | SEC Form 4 |
| DAVIS STEPHEN | ACAD | CEO | Mar 25 '24 | Sell | $17.90 | 17,714 | $317,080.60 | 118,842 | SEC Form 4 |
| Schneyer Mark C. | ACAD | EVP, CHIEF FINANCIAL OFFICER | Mar 25 '24 | Sell | $17.90 | 5,434 | $97,268.60 | 26,183 | SEC Form 4 |
| Teehan Brendan | ACAD | EVP, COO, HEAD OF COMMERCIAL | Mar 25 '24 | Sell | $17.90 | 5,140 | $92,006.00 | 36,340 | SEC Form 4 |
| Kihara James | ACAD | PRINCIPAL ACCOUNTING OFFICER | Feb 23 '24 | Sell | $24.67 | 474 | $11,693.58 | 11,391 | SEC Form 4 |
| Schneyer Mark C. | ACAD | EVP, CHIEF FINANCIAL OFFICER | Feb 23 '24 | Sell | $24.67 | 772 | $19,045.24 | 21,067 | SEC Form 4 |
| Teehan Brendan | ACAD | EVP, COO, HEAD OF COMMERCIAL | Feb 23 '24 | Sell | $24.67 | 624 | $15,394.08 | 31,432 | SEC Form 4 |
| DAVIS STEPHEN | ACAD | CEO | Jan 6 '24 | Sell | $29.96 | 3,732 | $111,810.72 | 96,521 | SEC Form 4 |
| Teehan Brendan | ACAD | EVP, COO, Head of Commercial | Jan 6 '24 | Sell | $29.96 | 731 | $21,900.76 | 30,949 | SEC Form 4 |
| Kihara James | ACAD | Principal Accounting Officer | Dec 15 '23 | Sell | $28.30 | 2,000 | $56,600.00 | 11,025 | SEC Form 4 |
| Kihara James | ACAD | Principal Accounting Officer | Nov 17 '23 | Sell | $22.64 | 1,985 | $44,940.40 | 13,025 | SEC Form 4 |
Latest ACADIA Pharmaceuticals Inc. News
ACAD Breaking Stock News: Dive into ACAD Ticker-Specific Updates for Smart Investing
Business Wire
3 days ago
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
5 days ago
Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
Simply Wall St.
9 days ago
Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
GuruFocus.com
10 days ago
ACADIA Pharmaceuticals Q1 2024 Earnings: Solid Growth with New Product Launches
MT Newswires
10 days ago
UBS Cuts Price Target on ACADIA Pharmaceuticals to $25 From $27, Keeps Buy Rating
MT Newswires
10 days ago
Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $17 From $19, Maintains Perform Rating
Simply Wall St.
10 days ago
ACADIA Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Business Wire
11 days ago